Oncobiologics (ONS) Hit By Barclays Downgrade; Ing Asia Pacific High Dividend Equity Income Fund (IAE) Has 1.4 Sentiment

The stock increased 0.84% or $0.01 during the last trading session, reaching $1.2. About 16,911 shares traded. Oncobiologics, Inc. (NASDAQ:ONS) has 0.00% since January 29, 2017 and is . It has underperformed by 16.70% the S&P500.

The stock increased 1.43% or $0.16 during the last trading session, reaching $11.35. About 43,804 shares traded or 21.13% up from the average. Voya Asia Pacific High Dividend Equity Income Fund (IAE) has risen 20.83% since January 29, 2017 and is uptrending. It has outperformed by 4.13% the S&P500.

Oncobiologics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, manufacturing, and commercializing complex biosimilar therapeutics in immunology and oncology disease areas. The company has market cap of $30.64 million. The Company’s advanced product candidate is ONS-3010, an adalimumab biosimilar that is in a Phase 1 clinical trial, which targets the tumor necrosis factor alpha. It currently has negative earnings. The firm also develops ONS-1045, a bevacizumab biosimilar, which is in a Phase 1 clinical trial that interferes with tumor growth by binding to vascular endothelial growth factor, a protein that stimulates the formation of new blood vessels.

Fca Corp Tx holds 0.69% of its portfolio in Voya Asia Pacific High Dividend Equity Income Fund for 156,238 shares. Aviance Capital Partners Llc owns 86,342 shares or 0.31% of their US portfolio. Moreover, Oxbow Advisors Llc has 0.19% invested in the company for 92,299 shares. The Colorado-based Advisors Asset Management Inc. has invested 0.13% in the stock. 1607 Capital Partners Llc, a Virginia-based fund reported 197,159 shares.